MARKET

MRTX

MRTX

Mirati
NASDAQ

Real-time Quotes | Nasdaq Last Sale

102.29
+1.56
+1.55%
Opening 13:02 11/14 EST
OPEN
100.81
PREV CLOSE
100.73
HIGH
103.48
LOW
100.43
VOLUME
104.52K
TURNOVER
--
52 WEEK HIGH
111.99
52 WEEK LOW
34.39
MARKET CAP
4.03B
P/E (TTM)
-21.8279
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MRTX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

MRTX News

  • Mirati Therapeutics Presents Data From Ongoing Clinical Trials Of Sitravatinib In Combination With Nivolumab At The SITC 34th Annual Meeting
  • PR Newswire.4d ago
  • 3 Cancer Treatment Stocks to Buy Right Now
  • MotleyFool.com.4d ago
  • Mirati (MRTX) Reports Q3 Loss, Tops Revenue Estimates
  • Zacks.11/04 23:55
  • Mirati Therapeutics Q3 EPS $(1.38) Down From $(0.85) YoY
  • Benzinga.11/04 21:36

More

Industry

Biotechnology & Medical Research
-0.07%
Pharmaceuticals & Medical Research
-0.45%

Hot Stocks

Name
Price
%Change

About MRTX

Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of targeted oncology products. The Company's clinical pipeline consists of three product candidates: MGCD265, MGCD516 and mocetinostat. MGCD265 and MGCD516 are orally-bioavailable, spectrum-selective kinase inhibitors. Both MGCD265 and MGCD516 are in development to treat patients with non-small cell lung cancer (NSCLC), and other solid tumors. MGCD265 is in Phase Ib clinical development and MGCD516 is in the dose escalation phase of Phase I clinical development. Mocetinostat is an orally-bioavailable, spectrum-selective histone deacetylase (HDAC), inhibitor, which is in Phase II development. Mocetinostat is being developed for the second line treatment of patients with bladder cancer and non-hodgkins lymphoma (NHL), specifically focusing on diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL).
More

Webull offers Mirati Therapeutics Inc (MRTX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.